PRESS RELEASE : Immunic, Inc. Announces EMPhASIS -2-

conditions, if any, that may be supported by the company's phase 2 EMPhASIS trial data; future analysis of the EMPhASIS 
trial data and presentations related thereto; the potential availability and frequency of administration of IMU-838 as 
a potential treatment for patients with relapsing-remitting multiple sclerosis or for patients with other conditions; 
preparations for a clinical phase 3 program for IMU-838 in relapsing-remitting multiple sclerosis; the nature, strategy 
and focus of the company and further updates with respect thereto; and the development and commercial potential of any 
product candidates of the company. Immunic may not actually achieve the plans, carry out the intentions or meet the 
expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on 
these forward-looking statements. Such statements are based on management's current expectations and involve risks and 
uncertainties. Actual results and performance could differ materially from those projected in the forward-looking 
statements as a result of many factors, including, without limitation, the COVID-19 pandemic, risks and uncertainties 
associated with the ability to project future cash utilization and reserves needed for contingent future liabilities 
and business operations, the availability of sufficient resources to meet business objectives and operational 
requirements, the fact that the results of earlier studies and trials may not be predictive of future clinical trial 
results, the protection and market exclusivity provided by Immunic's intellectual property, risks related to the drug 
development and the regulatory approval process and the impact of competitive products and technological changes. A 
further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned 
"Risk Factors," in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2020, filed with the 
SEC on February 26, 2021, and in the company's subsequent filings with the Securities and Exchange Commission. Copies 
of these filings are available online at www.sec.gov or ir.imux.com/sec-filings. Any forward-looking statement made in 
this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these 
forward-looking statements to reflect events or circumstances that exist after the date on which they were made. 
Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of 
this press release. 
Contact Information 
Immunic, Inc. 
Jessica Breu 
Head of Investor Relations and Communications 
[phone] 
[e-mail] 
US IR Contact 
Rx Communications Group 
Paula Schwartz 
[phone] 
[e-mail] 
US Media Contact 
KOGS Communication 
Edna Kaplan 
[phone] 
[e-mail] 
=---------------------------------------------------------------------------------------------------------------------- 
2021-04-15 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
=---------------------------------------------------------------------------------------------------------------------- 

1185222 2021-04-15

(END) Dow Jones Newswires

April 15, 2021 06:32 ET (10:32 GMT)